Pediatric heart transplantation (HTx) remains an important treatment option in the care of
children with end-stage heart disease, whether it is secondary to cardiomyopathy or …

Common indications for PHTx include end-stage congenital heart disease and
cardiomyopathy. Current median graft survival among PHTx recipients ranges from 13 to 22 …

Background—Since the initial utilization of heart transplantation as therapy for end-stage
pediatric heart disease, improvements have occurred in outcomes with heart transplantation …

Objective: Early and late mortality have significantly improved during recent decades in
pediatric patients after heart transplantation (HTx). Nevertheless early and late morbidity and …

The PHTS was founded in 1991 as a not‐for‐profit organization dedicated to the
advancement of the science and treatment of children during listing for and following heart …

Pediatric heart transplantation has grown worldwide since the first procedure in 1967. With
more than 11,000 transplants in children reported, the Registry of the International Society …

Due to impressive improvements in surgical repair options, even patients with complex
congenital heart disease (CHD) may survive into adulthood and have a high risk of end …

End-stage congenital heart disease (CHD) is an important indication for pediatric heart
transplantation (HTx) as well as transplantation in adult populations. The purpose of this …

The first pediatric heart transplantation was performed in 1967. Since then 10,000
transplants in children have been reported to the registry of the International Society for …

With growing numbers of children with complex congenital heart disease surviving initial
surgical procedures, more patients are presenting in later childhood or early adulthood in …